Prostate cancer cell survival pathways activated by bone metastasis microenvironment

Journal of Musculoskeletal Neuronal Interactions

Volumn 5, Issue 2, 2005, Pages 135-144

  Tenta, R ^a   Sotiriou, E ^a   Pitulis, N ^a   Thyphronitis, G ^a   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Androgen refractoriness; Bone metastatis; Prostate cancer; Survival factors

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; ANTINEOPLASTIC AGENT; GROWTH PROMOTOR;

APOPTOSIS; BONE METASTASIS; CANCER CELL; CANCER THERAPY; CELL PROTECTION; CELL SURVIVAL; DRUG RESPONSE; DRUG TARGETING; HUMAN; MALE; PATHOPHYSIOLOGY; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; BONE TUMOR; DRUG RESISTANCE; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GROWTH SUBSTANCES; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 25444433796     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004; 91:483-490.
2. Culig Z, Klocker H, Bartsch G, Steiner G, Hobisch A. Androgen receptors in prostate cancer. J Urol 2003; 170:1363-1369.
3. Labrie F. Combined androgen blockade and treatment of localized prostate cancer: a real hope when approaching the year 2000. Endocr Relat Cancer 1998; 5:341-351.
4. Mohler JL, Gregory CW, Ford OH 3III. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10:440-448.
5. Koutsilieris M, Dimopoulos MA, Doillon C, Reyes-Moreno C, Choki I. The molecular concept of prostate cancer. Cancer J 1996; 9:89-94.
6. Koutsilieris M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol Hematol 1995; 18:51-64.
7. Koutsilieris M, Mitsiades C, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A. Combination of somatostatin analog, low-dose dexamethasone and standard androgen ablation therapy for stage D3 prostate cancer patients with bone metastases. Clin Cancer Res 2004;10:4398-4405.
8. Mitsiades C, Koutsilieris M. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opin Investig Drugs 2001; 10:1099-1115.
9. Koutsilieris M, Mitsiades C, Dimopoulos T, Vacalicos J, Lambou T, Tsintavis A, Milathianakis C, Bogdanos J, Karamanolakis D. Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer. Expert Opin Investig Drugs 2002; 21:283-293.
10. Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical response to luteinizing-hormone releasing-hormone analog in androgen ablation-refractory prostate cancer. J Clin Endocrinol Metab 2001; 86:5729-5736.
11. Koutsilieris M, Tzanela M, Dimopoulos T. Novel concept of anti-survival factor (ASF) therapy produces an objective clinical response in patients with hormone-refractory prostate cancer. Prostate 1999; 38:313-316.
12. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vesselle R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to anti-androgen therapy. Nat Med 2004; 10:33-39.
13. Wallen MJ, Linja M, Kaartinen K, Schleutker J, Visakorpi T. Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol 1999; 189:559-563.
14. Heinlein CA, Chang C. Androgen receptor (AR) co-regulators: an overview. Endocr Rev 2002; 23:175-200.
15. Linja MJ, Porkka KP, Kang Z, Savinainen KJ, Janne OA, Tammela TL, Vessella R, Palvimo JJ, Visakorpi T. Expression of androgen receptor co-regulators in prostate cancer. Clin Cancer Res 2004; 10:1032-1040.
16. Evangelou AI, Winter SF, Huss WJ, Bok RA, Greenberg NM. Steroid hormones, polypeptide growth factors, hormone-refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem 2004; 91:671-683.
17. Bogdanos J, Karamanolakis J, Tenta R, Tsintavis A, Milathianakis C, Mitsiades C, Koutsilieris M. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocr Relat Cancer 2003; 10:279-289.
18. Karamanolakis D, Bogdanos J, Sourla A, Milathianakis C, Tsintavis A, Lembessis P, Tenta R, Tiblalexi D, Koutsilieris M. Molecular evidence-based use of bone resorption-targeted therapy in prostate cancer patients at high risk for bone involvement. Mol Med 2002; 8:667-674.
19. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 2002; 9:61-73.
20. Koutsilieris M, Mitsiades C, Sourla A. Insulin-like growth factor 1 and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer. Mol Med 2000; 6:251-267.
21. Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop 2003; 415 (Suppl.):67-74.
22. Tenta R, Tiblalexi D, Sotiriou E, Lembessis P, Manoussakis M, Koutsilieris M. Bone microenvironment-related growth factors modulate differentially the anti-cancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells. Prostate 2004; 59:120-131.
23. Djakiew D. Deregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000; 42:150-160.
24. Sadar MD, Hussain M, Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 1999; 6:487-502.
25. Mundy GR, Guise TA. Role of parathyroid hormone-related peptide in hypercalcaemia of malignancy and osteolytic bone disease. Endocr Relat Cancer 1998; 5:15-26.
26. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY. A parathyroid hormone-related protein implicated in malignant hypercalcaemia: cloning and expression. Science 1987; 237:893-896.
27. Karaplis AC, Luz A, Glowacki J, Bronson RT, Tybulewicz VL, Kronenberg HM, Mulligan RC. Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev 1994; 1:277-289.
28. Qian J, Colbert MC, Witte D, Kuan CY, Gruenstein E, Osinska H, Lanske B, Kronenberg HM, Clemens TL. Midgestational lethality in mice lacking the parathyroid hormone (PTH)/PTH-related peptide receptor is associated with abrupt cardiomyocyte death. Endocrinology 2003; 144:1053-1061.
29. Scluter KD. PTH and PTHP: similar structures but different functions. News Physiol Sci 1999; 14:243-248.
30. Gardella TJ, Jüppner H. Molecular properties of the PTH/PTHrP receptor. Trends Endocrinol Metab 2001; 12:210-217.
31. Henderson JE, Amizuka N, Warshawsky H, Biasotto D, Lanske BM, Goltzman D, Karaplis AC. Nucleoral localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. Mol Cell Biol 1995; 115:4064-4075.
32. Veronica A, Sepulveda T, Falzon M. Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways. Regul Peptides 2002; 105:109-120.
33. Veronica A, Sepulveda T, Shen X, Falzon M. Intracrine PTHrP protects against serum-starvation-induced apoptosis and regulates the cell cycle in MCF-7 breast cancer cells. Endocrinology 2002; 143:596-606.
34. Amling M, Neff L, Tanaka S, Inoue D, Kuida K, Weir E, Philbrick WM, Broadus AE, Baron R. Bcl-2 lies down-stream of parathyroid hormone-related peptide in a signaling pathway that regulates chondrocyte maturation during skeletal development. J Cell Biol 1997; 136:205-213.
35. Li X, Drucker DJ. Parathyroid hormone-related peptide is a downstream target for ras and src activation. J Biol Chem 1994; 269:6263-6266.
36. Aklilu F, Gladu J, Goltzman D, Rabbani SA. Role of mitogen-activated protein kinases in the induction of parathyroid hormone-related peptide. Cancer Res 2000; 60:1753-1760.
37. Bakin RE, Gioeli D, Bissonette EA, Weber MJ. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 2003; 63:1975-1980.
38. Bryden AAG, Islam S, Freemont AJ, Shanks JH, George NJR, Clarke NW. Parathyroid hormone-related peptide: expression in prostate cancer bone metastases. Prostate Cancer P D 2002; 5:59-62.
39. Pizzi H, Gladu J, Carpio L, MiaoD, Goltzman D, Rabbani SA. Androgen regulation of parathyroid hormone-related peptide production in human prostate cancer cells. Endocrinology 2003; 144:858-867.
40. Koutsilieris M, Frenette G, Lazure C, Lehoux JG, Govindan MV, Polychronakos C. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res 1993; 13:481-486.
41. Deftos LJ. Prostate Carcinoma (Production of bioactive factors). Cancer suppl (Skeletal Complications of malignancy) 2000; 88:3002-3008.
42. Barrack ER. TGFβ in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 1997; 31:61-70.
43. Sheng Shijie. The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Met Rev 2001; 20:287-296.
44. Miyazono Y, ten Dijke P, Heldin CH. TGF-beta signaling by Smad proteins. Adv Immunol 2000; 75:115-157.
45. Derynck R. TGF-β receptor-mediated signaling. Trends Biochem Sci 1994; 19:548-553.
46. Kawabata M, Imamura T, Inoue H, Hanai J, Nishihara A, Hanyu A, Takase M, Ishidou Y, Udagawa Y, Oeda E, Goto D, Yagi K, Kato M, Miyazono K. Intracellular signaling of the TGF-β superfamily by Smad proteins. Ann NY Acad Sci 1999; 886:73-82.
47. Massague J, Hata A, Liu F. TGF-β signaling through the Smad pathway. Trends Cell Biol 1997; 7:187-192.
48. Hoi ME. Mechanism of transforming growth factor-β1 signaling: role of the mitogen-activated protein kinase. Kidney Int 2000; 58, suppl.77:53-58.
49. Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BY, Park YK, Chi SG. Transforming growth factor-β1. activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kB, JNK, and Ras signaling pathways. Oncogene 2003; 22:4314-4332.
50. Tiecker BA. Malignant cells, directors of the malignant process: Role of transforming growth factor-beta. Cancer Met Rev 2001; 20:133-143.
51. De Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor- β signaling in cancer. J Natl Cancer Inst 2000; 92:1388-1397.
52. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardno PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor - β1 in patients with metastatic prostatic carcinoma. J Urol 1999; 161:182-187.
53. Wang HS, Chard T. IGFs and IGF-binding proteins in the regulation of human ovarian and endometrial function. J Endocrinol 1999; 161:1-13.
54. Le Roith D, Werner H, Beitner-Johnson D, Roberts CT. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16:143-163.
55. DeBosch BJ, Deo BK, Kumagai AK. Insulin-like growth factor-1 effects on bovine retinal endothelial cell glucose transport: role of MAP kinase. J Neurochem 2002; 81:728-734.
56. Nissley P, Lopaczynski W. Insulin-like growth factor receptors. Growth Factors 1991; 5:29-49.
57. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res 1999; 253:1-6.
58. Silha JV, Murphy LJ. Minireview: Insights from insulin-like growth factor binding protein transgenic mice. Endocrinology 2002; 143:3711-3714.
59. Rosenfeld RG. The blind men and the elephant-a parable for the study of insulin-like growth factor binding proteins. Endocrinology 1998; 118:1743-1758.
60. Jones JL, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16:3-34.
61. Dimopoulos MA, Kiamouris C, Gika D, Deliveliotis C, Giannopoulos A, Zervas A, Alamanis C, Constantinidis C, Koutsilieris M. Combination of LHRH-Analogue with somatostatin analogue and dexamethasone vs chemotherapy in hormone-refractory prostate cancer patients: a randomized phase II study. Urology 2004; 63:120-125.
62. Baxter RC. Signaling pathways involved in antiproliferative effects of IGFBP-3: a review. J Clin Pathol: Mol Pathol 2001; 54:145-148.
63. Basilico C, Moscatelli D. the FGF family of growth factors and oncogenes. Adv Cancer Res 1992; 59:115-165.
64. Dow JK, De Vere White RW. Fibroblast growth factor 2: It's structure and property, paracrine function, tumor angiogenesis and prostate-related mitogenic and oncogenic functions. Urology 2000; 55:800-806.
65. Sherwood ER, Fong CJ, Lee C, Kozlowski JM. Basic fibroblast growth factor: a potential mediator of stromal growth in the human prostate. Endocrinology 1992; 130:2955-2963.
66. Rosini P, Bonaccorsi L, Baldi E, Chiasserini C, Forti G, De Chiara G, Lucibello M, Mongiat M, Lozzo RV, Garaci E, Cozzolino F, Torcia MG. Androgen expression induces FGF2, FGF-binding protein production and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival and androgen receptor down-modulation. Prostate 2002; 53:310-321.
67. Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z, Ramoner R, Zhang J, Bartsch G Reissigl A, Radmayr C, Thurnher M, Klocker H. Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 1997; 31:223-233.
68. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor indices angiogenesis in vitro. Proc Natl Acad Sci USA 1986; 83:7297-7301.
69. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
70. Van der Pluijm G. Mécanismes impliqués dans l'invasion de l'os par les cellules tumorales. Rev Rhum (Ed. Fr.) 2002; 69:1002-1009.
71. Keer HN, Gaylis FD, Kozlowski JM, Kwaan HC, Bauer KD, Sinha AA, Wilson MJ. Heterogeneity in plasminogen-activator (PA) levels in human prostate-cancer cell line: increased PA activity correlates with biologically aggressive behavior. Prostate 1991; 18:201-214.
72. Sobue T, Gravely T, Hand A, Min YK, Pilbeam C, Raisz LG, Zhang X, Larocca D, Florkiewicz R, Hurley MM. Regulation of fibroblast growth factor 2 and fibroblast growth factor receptors by transforming growth factor β in human osteoblastic MG-63 cells. J Bone Min Res 2002; 17:502-512.
73. Hrzenjak M, Shain SA. Fibroblast growth factor-2 and TPA enhance prostate-cancer-cell proliferation and activate members of the Ras and PKC signal transduction pathways. Recept Signal Transduct 1997; 7:207-219.
74. Schamberger C, Cerni C. Mapk/Sapk signaling in apoptosis and bFGF-mediated survival. Sci World J 2001; 1:43.
75. Zuck B, Goepfert C, Nedlin-Chittka A, Sohrt K, Voigt KD, Knabbe C. Regulation of fibroblast growth factor-like protein(s) in the androgen-responsive human prostate carcinoma cell line LNCaP. J Steroid Biochem Mol Biol 1992; 41:659-663.
76. Swolin-Eide D, Ohlsson C. Effects of cortisol on the expression of interleukin-6 and interleukin-1β in human osteoblast-like cells. J Endocrinol 1998; 156:107-114.
77. Roodman GD. Interleukin-6: an osteotropic factor. J Bone Miner Res 1992; 7:475-478.
78. De La Mata J, Uy H, Guise TA, Story B, Boyce BF, Mundy GR, Goodman GD. IL-6 enhances hypercalcaemia and bone resorption mediated by PTHrP in vivo. J Clin Invest 1995; 95:2846-2852.
79. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995; 45:542-549.
80. Culig Z, Bartsch G, Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol 2002; 197:231-238.
81. Ihle JN. Cytokine receptor signaling. Nature 1995; 377:591-594.
82. Ernst M, Oates A, Dunn AR. Gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein kinase pathways. J Biol Chem 1996; 271:30136-30143.
83. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002; 277:7076-7085.
84. Yang L, Wang L, Lin HK. Interleukin-6 differentially regulates androgen receptor transactivation ia PI3K-Akt, STAT3, and MAPK, three dinstict signal pathways in prostate cancer cells. Biochem Biophys Res Commun 2003; 305:462-469.
85. Akakura K, Suzuki H, Ueda T, Komiya A, Ichikawa T, Igarashi T, Ho H. Possible mechanism of dexamethasone therapy for prostate cancer suppression of circulating level of inerleukin-6. Prostate 2003; 56:106-109.
86. Guise TA, Mohammad KS. Endothelins in bone cancer metastases. Cancer Treat Res 2004; 118:197-212.
87. Le Roy BE, Sellers RS, Rosol TJ. Canine prostate stimulates osteoblast function using the endothelin receptors. Prostate 2004; 59:148-156.
88. Hamdy FC. Endothelin and skeletal metastases in hormone-refractory prostate cancer. Eur Urology Suppl 2003; 2:15-19.
89. Granchi S, Brocchi S, Bonaccorsi L, Baldi E, Vinci MC, Frti G, Serio M, Maggi M. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 2001; 49:267-277.
90. Gohji K, Kitazawa S, Tamada H. Expression of endothelin receptor A associated with prostate cancer progression. J Urol 2001; 165:1033-1036.
91. Miyata Y, Sakai H, Hayashi T, Kanetake H. Serum insulin-like growth factor binding protein 3/prostate specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 2003; 54:125-132.
92. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90:911-915.
93. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 1998; 279:563-565.